CytoGenix Announces Notice of Allowance in Australia for Single Stranded DNA Expression Vector Patent
Tuesday January 15, 12:31 pm ET
HOUSTON--(BUSINESS WIRE)--CytoGenix, Inc. (OTCBB:CYGX) announced today it has received a notice of allowance for a patent on its original single stranded DNA expression plasmid vectors in Australia. The patent, entitled “Production of ssDNA in vivo,” claims both compositions and methods for using the single stranded DNA expression vectors. The subject matter includes several variations of the expression vector system for inducing cells to produce specifically designed single strands of DNA which may be used in antisense, aptamer, triplex or DNA enzyme applications. The claimed system provides a more advanced and flexible approach for using the Company’s proprietary ssDNA expression system.
ADVERTISEMENT
“The award of this allowance provides further validation of CytoGenix technology and improves the Company’s ability to secure strategic partners that can assist in commercialization of CytoGenix products using this ssDNA expression system,” stated Malcolm Skolnick, CytoGenix President and Chief Executive Officer.
Dr. Yin Chen, Chief Scientific Officer and co-inventor of the technology, comments, "This is a significant step forward for CytoGenix because the technology has broad application in potential therapeutics and high-throughput drug screening.”
CytoGenix, Inc. is a Houston-based biopharmaceutical company pioneering the new field of gene based medicine and is focused on developing innovative vaccines and therapeutic products using its three proprietary technology platforms: synDNATM enzymatic, non-bacterial production methodology, single stranded DNA (ssDNA) expression, and oligonucleotide based anti-bacterial technologies. CytoGenix currently holds 13 granted patents, 2 allowances, and 55 additional international or US patent applications claiming methods and materials in connection with these platform technologies.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the Company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact:
CytoGenix, Inc., Houston
VP of Finance and Administration
Chief Financial Officer
Greg Taylor, 713-789-0070
or
Investor Relations
Parag Dave, 917-322-2585
pdave@otccommunications.com
